[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624968":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":40,"centralContacts":44,"locations":52,"responsibleParty":72,"collaborators":74,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":79,"sex":85,"minAge":86,"maxAge":39,"enrollmentInfo":87,"targetDuration":39,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":39,"overallStatus":55,"whyStopped":39,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Main Study Treatment Period: NXT007 Prophylaxis","EXPERIMENTAL","Participants randomized to this arm will receive NXT007 prophylaxis for the main study treatment period.",[13],"Combination Product: NXT007",{"label":15,"type":16,"description":17,"interventionNames":18},"Main Study Treatment Period: FVIII SOC Prophylaxis","ACTIVE_COMPARATOR","Participants randomized to this arm will receive FVIII standard of care (SOC) prophylaxis for the main study treatment period.",[19],"Drug: Human Coagulation Factor VIII",{"label":21,"type":10,"description":22,"interventionNames":23},"Open-Label Extension Period: NXT007 Prophylaxis","After the main study treatment period, participants in the NXT007 arm will be able to continue with NXT007 dosing, and participants in the FVIII arm will be able to switch to NXT007, in the open-label extension period.",[13],[25,34],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"COMBINATION_PRODUCT","NXT007","NXT007 will be administered subcutaneously (SC) using an integrated drug-device combination product.",[9,21],[31,32,33],"Zemocimig","RO7589655","RG6512",{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","Human Coagulation Factor VIII","Factor VIII (FVIII) prophylaxis standard of care (SOC) will be administered at the dose and frequency as stated in the local labels and per local country practice.",[15],null,[41],{"name":42,"affiliation":5,"role":43},"Clinical Trials","STUDY_DIRECTOR",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":39,"email":49},"Reference Study ID Number: WO45886 https:\u002F\u002Fforpatients.roche.com\u002F","CONTACT","888-662-6728 (U.S. Only)","global-roche-genentech-trials@gene.com",{"name":51,"role":47,"phone":39,"phoneExt":39,"email":39},"Fastest response: use the inquiry form. No email attachments. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[53,67],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":39},"Nara Medical University Hospital","RECRUITING","Kashihara-shi","Nara","634-8522","Japan","JP",{"type":62,"coordinates":63},"Point",[64,65],135.7929,34.50896,{"lat":65,"lon":64},{"facility":68,"status":55,"city":69,"state":70,"zip":71,"country":59,"countryCode":60,"cosmosGeoPoint":39,"geoPoint":39,"contacts":39},"Tokyo Medical University Hospital","Shinjuku-Ku","Tokyo","160-0023",{"type":73,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR",[75],{"name":76,"class":6},"Chugai Pharmaceutical","100624968","phase-3-a-clinical-study-to-evaluate-the-effects-of-nxt007-compared-to-factor-viii-prophylaxis-in-participants-with-hemophilia-a-100624968",false,"NCT07416526","A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A","A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Factor VIII Prophylaxis in People With Hemophilia A Without Inhibitors","ZEBRHA 1","Inclusion Criteria:\n\n* Diagnosis of severe (FVIII:C \\\u003C1 IU\u002FdL \\[International Unit per decilitre\\]) or moderate (FVIII:C between ≥1 IU\u002FdL and ≤5 IU\u002FdL) congenital hemophilia A without inhibitors against FVIII\n* No documented inhibitor (i.e., \\\u003C0.6 BU\u002FmL \\[Bethesda unit per millilitre\\]), FVIII half-life ≥6 hours, or FVIII recovery \\>66% in the last 3 years prior to screening\n* Documented historical negative test for FVIII inhibitor (i.e., \\\u003C0.6 BU\u002FmL) within 12 months prior to enrollment\n* Documentation of the details of prophylactic and episodic FVIII treatment and of the number and type of bleeding episodes for at least the last 6 months prior to screening\n* Agreement to adhere to the contraception requirements (for potential participants with childbearing potential)\n\nExclusion Criteria:\n\n* Sensitivity to any of the study investigations, or components thereof, or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study\n* Use of systemic immunomodulators (e.g., interferon or rituximab) at the time of enrollment or planned use during the study, except for anti-retroviral therapy to treat HIV\n* Planned surgery (excluding minor procedures such as non-molar tooth extraction, incision and drainage) during the study\n* History or presence of an abnormal ECG that is deemed clinically significant, (e.g., complete left bundle branch block, second- or third- degree atrioventricular heart block) or ECG evidence or clinical history of prior myocardial infarction\n* Refusal to accept plasma-derived and\u002For blood product transfusion support in an emergency scenario\n* History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing)","ALL","12 Years",{"count":88,"type":89},126,"ESTIMATED","INTERVENTIONAL",[92],"PHASE3","The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without inhibitors. The study will include people aged ≥12 years old with severe or moderate congenital hemophilia A without inhibitors on previous FVIII prophylaxis treatment.",[95],"Hemophilia A","2026-06-04",{"date":98,"type":99},"2026-06-08","ACTUAL",{"date":101,"type":99},"2026-05-15",{"date":103,"type":89},"2031-09-23",{"name":5,"class":6},2]